MIT-Harvard Center of Cancer Nanotechnology Excellence

麻省理工学院-哈佛大学癌症纳米技术卓越中心

• 批准号: 7976489
• 负责人: ROBERT Samuel LANGER
• 金额: $ 229.54万
• 依托单位: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7976489
• 关键词: MIT; Harvard; Center; Cancer; Nanotechnology

The overall goal of this U54 application is to support a highly multidisciplinary team of expert chemists, engineers, biologists, material scientists and clinicians to develop and rapidly translate new nanotechnologies to better diagnose and treat cancer in the clinic. This team formed a Center for Cancer Nanotechnology Excellence (CCNE) in 2004 and over the past 5 years has shown extraordinary productivity through its integrated research programs and shared resources. The primary team includes investigators from Massachusetts Institute of Technology (MIT), Harvard Medical School (HMS), Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) and Harvard Faculty of Arts and Sciences (FAS). The CCNE thus effectively bridges programs in basic sciences at two Universities (MIT and Harvard) and clinical programs at leading Hospitals (MGH and BWH). The program will continue to be headed up by Dr. Robert Langer and Dr. Ralph Weissleder as Co-Pls. Dr. Langer is Institute Professor at MIT and member of the Koch Institute for Integrative Cancer Research at MIT (Kl). Dr. Weissleder is a Professor at Harvard Medical School, the Director of the Center for Systems Biology at MGH, a practicing clinician at MGH and a member of the Dana Farber Harvard Cancer Center. Public Health Relevance: With recent advances in nanotechnology and the introduction of some new nanomaterials into clinical trials, a myriad of opportunities are available to advance medical science and disease treatment. The translational goal is now to better control and manipulate emerging new materials by precisely configuring molecular structures, adding biological functionalities, decreasing or eliminating toxicities, and creating supramolecular

该U54应用程序的总体目标是支持高度多学科的专家化学家，工程师，生物学家，物质科学家和临床医生，以开发并迅速转化新的纳米技术，以更好地诊断和治疗诊所。该团队在2004年成立了卓越癌症纳米技术中心（CCNE），在过去的5年中，通过其综合研究计划和共享资源表现出了非凡的生产力。小组包括马萨诸塞州理工学院（MIT），哈佛医学院（HMS），马萨诸塞州综合医院（MGH）以及杨百翰和妇女医院（BWH）以及哈佛艺术与科学学院（FAS）的研究人员。因此，CCNE有效地介绍了两所大学（麻省理工学院和哈佛）基础科学的计划，以及领先医院（MGH和BWH）的临床计划。该计划将继续由Robert Langer博士和Ralph Weissleder博士担任Co-Pls。 Langer博士是MIT的研究所教授，也是MIT（KL）的Koch综合癌症研究所成员。 Weissleder博士是MGH系统生物学中心主任的哈佛医学院教授，​​MGH的执业临床医生，Dana Farber Harvard Cancer Center的成员。 公共卫生相关性：随着纳米技术的最新进展，并将一些新的纳米材料引入临床试验中，因此有无数的机会来推进医学和疾病治疗。转化目标现在是通过精确配置分子结构，增加生物学功能，降低或消除毒性并创造超分子来更好地控制和操纵新的材料